Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
about
Human cytosolic 5'-nucleotidase I: characterization and role in nucleoside analog resistanceCombinatorial approaches to the prevention and treatment of HIV-1 infectionPreclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer.Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancerGemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patientsAccurate non-invasive image-based cytotoxicity assays for cultured cells.Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cellsEnhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.Novel combination chemotherapy in the treatment of non-small cell lung cancer.Overcoming platinum resistance in ovarian carcinoma.Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial.Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials.Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Antimetabolite incorporation into DNA: structural and thermodynamic basis for anticancer activity.Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas.Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.Adjuvant and neoadjuvant treatment in pancreatic cancerAnalysis of the cytotoxic activity of carboplatin and gemcitabine combination.Role of gemcitabine in cancer therapy.Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rateMechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancerPreclinical relevance of dosing time for the therapeutic index of gemcitabine-cisplatin.Pancreatic cancer: a review of recent advances.HER family inhibitors in pancreatic cancer: current status and future directions.Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeuticsComplete remission of platinum-refractory primary Fallopian tube carcinoma with third-line gemcitabine plus cisplatin: A case report and review of the literature.Role of platinum agents in the management of advanced pancreatic cancer.Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer.A SPATIOTEMPORAL MODEL TO SIMULATE CHEMOTHERAPY REGIMENS FOR HETEROGENEOUS BLADDER CANCER METASTASES TO THE LUNG.Triplex-forming oligonucleotides targeting c-MYC potentiate the anti-tumor activity of gemcitabine in a mouse model of human cancer.Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer.Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.Diagnostic Microdosing Approach to Study Gemcitabine Resistance.Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360).
P2860
Q24290673-592C5704-1D86-4029-BAC7-A37281F2608FQ30400060-0C08995C-9800-4FE2-991A-D013DA6ED803Q31927266-C2B94BA6-8F71-41B7-B4CA-456D9EE6E717Q33338535-9E5D265D-3D52-4BDF-B3C8-382CF939B5C2Q33347071-CC342DC5-555B-4EB2-829F-AEAE55E6A6C2Q33360212-581AFA4A-14B1-4C34-9769-2E61205CAC14Q33365711-6C40635A-3B0E-42A7-9548-50E168B014F9Q33395417-A48CD05D-CCEA-432C-B686-364AABE27844Q33396393-B413C615-55B5-43EC-8F4D-B0D9C3AA2253Q33610821-ED8E8DA4-08EA-4C7E-BC1A-36571ACA5D9CQ33670961-9EB23EB4-ECC6-4C1A-BEFD-35F31024FEA8Q33965570-097C0A9D-8799-4125-9C60-B2FEE7CB9420Q34181910-1650927D-3543-4A72-87E1-C5C8AB4C7B8CQ34233273-2B33B4C4-E2A2-43A9-A139-868531B64B6EQ34409341-B99ACB21-3D3C-4F08-9BDC-0E8DD9043FB1Q34576456-7960670C-9DBC-460C-89D8-F49CD3354CADQ34811103-41457E8B-FB5C-4B1D-824D-2E2290D9FD3AQ34850202-01DB248A-8FF3-4FF1-8A40-F8AC4E5B3A69Q35028999-7F11DBD5-D254-4F7A-87A5-BCA0FADBE056Q35612005-2E01CD48-D449-4E42-859E-FACD8B9E5831Q35886631-45EDE67C-C287-445B-A4C4-F18EBA22300BQ36035896-9093A988-3601-4429-B6BF-FDC9B072C847Q36429373-CAFA21FE-0D53-42C4-AC0F-D6791B8798C5Q36535928-9A659F2C-65F9-4561-B956-99C71544A7EDQ36609769-44E42190-6AE8-4C31-AACB-C20ADB9F93A4Q36610441-1ACF8239-6C32-4B46-B479-96C81F029D40Q36616830-E9896FE6-3A1C-4511-B56D-EE02C6BAB621Q36623071-AF1CF4F2-0F77-466D-A06D-9A0DE4E84566Q36734936-04F0AFC1-DEA6-4427-BE52-782C9FA0D878Q36866689-DE7D92EF-058C-4C01-B289-90E5CF17529AQ36918550-333522F1-3E81-414E-B966-DD534CABDFB7Q36979302-F4F61533-7A52-4CC2-A521-E76DC511A541Q37013079-A4E3DC55-6783-4F47-B34C-CEBEB7001206Q37500149-FCAC14B8-6B54-4161-8E05-A2418224E491Q37732429-2A31204D-6701-47F8-808D-B51D76E546D8Q38325864-D79D2414-6E2A-49A6-A52F-2EF37460E25BQ38673319-4BF1176D-FB17-4FC6-92BA-2B85DAAAE0B6Q38744400-352517A9-A26A-498F-AF0A-15B73417E334Q39022032-6262FB21-9DC1-40E2-80A5-7492EC922EDBQ39094261-349404D4-F846-4017-9A00-B5437901CA65
P2860
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Mechanisms of synergism betwee ...... l-cell lung cancer cell lines.
@ast
Mechanisms of synergism betwee ...... l-cell lung cancer cell lines.
@en
type
label
Mechanisms of synergism betwee ...... l-cell lung cancer cell lines.
@ast
Mechanisms of synergism betwee ...... l-cell lung cancer cell lines.
@en
prefLabel
Mechanisms of synergism betwee ...... l-cell lung cancer cell lines.
@ast
Mechanisms of synergism betwee ...... l-cell lung cancer cell lines.
@en
P2093
P2860
P356
P1476
Mechanisms of synergism betwee ...... l-cell lung cancer cell lines.
@en
P2093
A M Bergman
C J van Moorsel
C M Kuiper
G J Peters
H M Pinedo
J B Vermorken
W J van der Vijgh
P2860
P2888
P304
P356
10.1038/SJ.BJC.6690452
P407
P577
1999-06-01T00:00:00Z
P5875
P6179
1004051184